BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MorphoSys AG Buys Sloning BioTechnology GmbH for $26.5M


10/8/2010 7:15:12 AM

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the acquisition of the private German company Sloning BioTechnology GmbH, a biotechnology company developing new methods of synthetic biology. The transaction will make MorphoSys the sole source of Sloning's state-of-the-art Slonomics technology, which dramatically improves the assembly and quality of protein libraries. By integrating Slonomics into its existing antibody technology platform, MorphoSys expects to improve the generation of drug candidates such that one in every two projects started reaches clinical development. The technology will also be used to accelerate the generation of both therapeutic and diagnostic antibodies. Sloning's shareholders received a one-off EUR 19 million cash payment upon signing.

"This acquisition secures our position at the forefront of antibody technology," commented Dr Simon Moroney, Chief Executive Officer of MorphoSys AG. "Sloning's unique technology is the most powerful method available for assembling protein libraries and has been proven to deliver superior products for a range of applications. We plan to use it to generate optimized antibodies much faster than can be done today and also to gain access to antibodies that simply can't be made with current technologies."

Sloning's patented core technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at pre-determined positions with unprecedented speed. This technology opens the way to a new and flexible approach to generating optimized proteins, such as antibodies.

"Current antibody generation technologies use an initial repertoire, which largely determines the properties of the resulting antibody. We intend to use Slonomics as the basis of a fundamentally different approach, which will rapidly test multiple generations of antibodies, equivalent to screening many billions of molecules, to isolate the best possible candidate", stated Dr Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "We expect to shorten the time needed to generate an antibody drug candidate by a third and even more importantly, to increase the proportion of programs reaching clinical development to 50%."

Sloning, founded in 2001, is a private company based in Puchheim, near Munich. The major shareholders are HBM BioVentures, KfW, LBBW Venture Capital and Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft. The company has developed and refined its proprietary technologies through collaborations with a number of pharmaceutical and industrial customers.

"We believe that the two companies' technology portfolios and extensive expertise will lead to superior therapeutic, diagnostic and industrial products," commented the Chief Executive Officer of Sloning, Dr Heinz Schwer, who will join MorphoSys, becoming a member of the senior management team.

"MorphoSys has the financial resources required to fully exploit the potential and capabilities of the Sloning technology platform and there is a strong fit in the culture of both companies," complements Dr Harald Poth, chairman of Sloning's advisory board.

Sloning's financial results will be fully consolidated into MorphoSys's accounts from today onwards. Today's transaction is not material in respect of MorphoSys's financial guidance for 2010.

MorphoSys will hold a public conference call tomorrow, October 08, at 02:00 p.m. CEST (08:00 a.m. EDT, 01:00 p.m. BST) to present key information on the acquisition of Sloning.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES